Validian (OTCMKTS: VLDI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for oncology and immune-mediated diseases. Since its founding in 2012, Validian has pursued a research-driven approach to identify and advance proprietary small molecules and biologics that target key drivers of tumor growth and chronic inflammation. The company’s R&D efforts are supported by an in-house bioinformatics platform designed to accelerate target validation and candidate selection.
Validian’s lead program, VLDI-101, is a selective inhibitor of a tumor-associated kinase implicated in multiple solid tumors, including non–small cell lung cancer and melanoma. Preclinical studies have demonstrated potent anti-tumor activity and a favorable safety profile, leading to the initiation of a Phase 1 clinical trial in 2022. In parallel, the company is developing VLDI-202, a monoclonal antibody designed to modulate the tumor microenvironment by reactivating exhausted T cells, with plans to file an investigational new drug (IND) application in the coming year.
Headquartered in Boston, Massachusetts, Validian operates a state-of-the-art research facility in Cambridge and maintains strategic partnerships with leading academic centers in the U.S. and Europe. These collaborations provide access to translational research expertise and specialized clinical trial networks, enabling the company to efficiently advance multiple assets through preclinical and early-stage clinical development.
Validian is led by CEO Dr. Alexandra Reid, who brings over 20 years of experience in oncology drug development, and COO Michael Chen, a veteran bioprocess engineer with a track record of scaling up biologics manufacturing. The company’s management team also includes seasoned executives in regulatory affairs, commercial strategy and corporate finance, positioning Validian to transition from research into late-stage development and, ultimately, commercialization.
AI Generated. May Contain Errors.
Free VLDI Stock Alerts